ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08785
0,04%
Bitcoin
66.715,40
0,67%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Sangamo Therapeutics Inc (SGMO)

  7. Sangamo Therapeutics Inc (SGMO) News

SGMO

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SGMO
DatumZeitQuelleÜberschriftSymbolFirma
09/05/202422h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SGMOSangamo Therapeutics Inc
09/05/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGMOSangamo Therapeutics Inc
09/05/202422h01Business WireSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:SGMOSangamo Therapeutics Inc
09/05/202414h05Business WireSangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome EditingNASDAQ:SGMOSangamo Therapeutics Inc
02/05/202422h15Business WireSangamo Therapeutics Announces First Quarter 2024 Conference Call and WebcastNASDAQ:SGMOSangamo Therapeutics Inc
22/04/202422h35Business WireSangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)NASDAQ:SGMOSangamo Therapeutics Inc
22/03/202413h05Business WireSangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct OfferingNASDAQ:SGMOSangamo Therapeutics Inc
13/03/202413h05Business WireSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:SGMOSangamo Therapeutics Inc
13/03/202413h01Business WireSangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPsNASDAQ:SGMOSangamo Therapeutics Inc
12/03/202423h30Business WireSangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and WebcastNASDAQ:SGMOSangamo Therapeutics Inc
27/02/202423h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
27/02/202423h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
27/02/202423h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
27/02/202423h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
27/02/202423h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
12/02/202414h05Business WireSangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry DiseaseNASDAQ:SGMOSangamo Therapeutics Inc
06/02/202422h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGMOSangamo Therapeutics Inc
06/02/202400h01Business WireSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety ProfileNASDAQ:SGMOSangamo Therapeutics Inc
26/01/202417h49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SGMOSangamo Therapeutics Inc
24/01/202422h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
24/01/202422h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
24/01/202422h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
24/01/202422h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
24/01/202422h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
19/01/202423h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGMOSangamo Therapeutics Inc
13/12/202313h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGMOSangamo Therapeutics Inc
28/11/202322h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
28/11/202322h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
28/11/202322h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
28/11/202322h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMOSangamo Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SGMO

Kürzlich von Ihnen besucht

TSXV
KDSX
Kadestone Capital
USOTC
GSDWW
Global Systems Dynamics (CE)
BIT
UC8XWH
Unicredit Bank
BITV
QTUMEUR
Qtum
BFNX
ELFETH
LSE
SHC
Shaftesbury Capital
NYSE
PGI
Premiere Global
BIT
UC72PA
Unicredit Bank
UNSW3
COKEUSDT
BitCoke Token
BOV
PEPB34R
PepsiCo
ASX
CPBCD
TSXV
OMM
Omineca Mining and Metals
ASX
IXC
Invex Therapeutics
TG
4NM1
China Evergrande New Ene...
NASDAQ
RENEW
Cartesian Growth Corpora...
COIN
EXNNUST
EXENO COIN
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten